Table 2 Cost inputs
From: Cost-effectiveness of fenofibrate for preventing diabetic complications in Australia
Cost | Source | |
|---|---|---|
Health outcomes | ||
Severe Visual Loss | $4,815 | AR-DRG: C61A, C61B |
Lower Extremity Amputation | $47,847 | AR-DRG: F11A, F11B, F13A, F13B |
End Stage Renal Disease | $10,376 | AR-DRG: L60A, L60B, L60C |
Ischemic Heart Disease | $3,468 | AR-DRG: F66A, F66B |
Heart Failure | $10,389 | AR-DRG: F62A, F62B, F62C |
First/subsequent MI | $8,467 | AR-DRG: F41A, F41B, F60A, F60B |
First/subsequent stroke | $12,380 | AR-DRG: B70A, B70B, B70C, B70D |
Medication (yearly cost) | ||
Fenofibrate | $203.00 | PBS item 13587D |
Metformin MR | $79.90 | PBS item 9435 N |
Gliclazide MR | $40.00 | PBS item 8535 F |
Other | ||
Complication free diabetes | $2,815 | Lee et al. 2018 |